Gelteq Opens Guangdong Center of Excellence to Tap $60B China Biotech
GELS•Gelteq has established a Center of Excellence in Guangdong Province, China, to accelerate product development, expand formulation and testing capabilities, and advance multiple programs concurrently. The hub positions the company to tap into the $60 billion Q1 cross-border biopharma licensing market and strengthen global commercialization.
1. Establishment of Center of Excellence
Gelteq has launched a new Center of Excellence in Guangdong Province, China, creating a regional hub for deeper integration with one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems. This facility will serve as a strategic gateway for the company’s drug delivery platform, enabling closer collaboration with local innovation networks and industry stakeholders.
2. Enhanced Development and Commercial Capabilities
The Guangdong hub will accelerate product development and commercialization timelines by expanding formulation, testing, and optimization capacities. It will also increase the company’s ability to advance multiple development programs simultaneously, improving operational scalability and efficiency across Gelteq’s global pipeline.
3. Strategic Market Positioning and Impact
Positioned in a market that saw nearly $60 billion in cross-border biopharma out-licensing deals in Q1 2026, the new center aligns Gelteq with leading biotechs using regional innovation hubs to enhance scalability. This move is expected to support near-term commercial opportunities and long-term pipeline growth by tapping into China’s robust licensing, partnership, and acquisition activities.
